Last reviewed · How we verify
Efficacy of Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.
Noninferiority trial to assess efficacy of fixed-dose combination of valsartan + rosuvastatin versus their isolated components in treatment of hypertension and dyslipidemia.
Details
| Lead sponsor | EMS |
|---|---|
| Phase | Phase 3 |
| Status | WITHDRAWN |
| Start date | 2019-10 |
| Completion | 2020-12 |
Conditions
- Hypertension
- Dyslipidemia
Interventions
- Valsartan 160mg + Rosuvastatin 20mg
- Valsartan 320mg + Rosuvastatin 20mg
- Diovan® 160mg + Crestor® 20mg
- Diovan® 320mg + Crestor® 20mg
Primary outcomes
- Reduction of systemic blood pressure measured between the first visit and last visit. — 8 weeks
- Percentage of participants who reach the goal of LDL-C according to intermediate risk rating ( LDLc < 100mg / dL ) and high risk ( LDLc < 70 mg / dL ) . — 8 weeks